Artiva Biotherapeutics, Inc. (ARTV)
NASDAQ: ARTV · Real-Time Price · USD
9.07
-1.68 (-15.63%)
At close: Apr 28, 2026, 4:00 PM EDT
9.04
-0.03 (-0.33%)
After-hours: Apr 28, 2026, 4:24 PM EDT
Artiva Biotherapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | - | 0.25 | 33.49 | 4.93 | 2 | |
| Revenue Growth (YoY) | - | -99.25% | 579.21% | 146.30% | - | |
| Gross Profit | - | 0.25 | 33.49 | 4.93 | 2 | |
| Selling, General & Admin | 20.27 | 17.21 | 13.91 | 20.78 | 12.86 | |
| Research & Development | 69.54 | 50.33 | 50.25 | 43.98 | 42.41 | |
| Operating Expenses | 89.81 | 67.53 | 64.16 | 64.76 | 55.27 | |
| Operating Income | -89.81 | -67.28 | -30.67 | -59.83 | -53.27 | |
| Interest & Investment Income | 5.96 | 5.35 | 2.54 | 1.29 | - | |
| Other Non Operating Income (Expenses) | -1.89 | -5.78 | -0.97 | -0.2 | -18.55 | |
| EBT Excluding Unusual Items | -85.75 | -67.72 | -29.1 | -58.74 | -71.83 | |
| Gain (Loss) on Sale of Investments | 1.88 | 2.34 | 0.46 | - | - | |
| Pretax Income | -83.87 | -65.37 | -28.65 | -58.74 | -71.83 | |
| Income Tax Expense | - | - | 0.07 | 0.05 | - | |
| Net Income | -83.87 | -65.37 | -28.72 | -58.79 | -71.83 | |
| Net Income to Common | -83.87 | -65.37 | -28.72 | -58.79 | -71.83 | |
| Shares Outstanding (Basic) | 24 | 11 | 1 | 1 | 1 | |
| Shares Outstanding (Diluted) | 24 | 11 | 1 | 1 | 1 | |
| Shares Change (YoY) | 117.11% | 1302.54% | 4.70% | 11.80% | 8.60% | |
| EPS (Basic) | -3.43 | -5.81 | -35.78 | -76.67 | -104.73 | |
| EPS (Diluted) | -3.43 | -5.81 | -35.78 | -76.67 | -104.73 | |
| Free Cash Flow | -79.34 | -55.67 | -50.69 | -57.13 | -17.03 | |
| Free Cash Flow Per Share | -3.25 | -4.95 | -63.14 | -74.51 | -24.83 | |
| Gross Margin | - | 100.00% | 100.00% | 100.00% | 100.00% | |
| Operating Margin | - | -26805.58% | -91.58% | -1213.32% | -2660.94% | |
| Profit Margin | - | -26045.02% | -85.75% | -1192.21% | -3587.66% | |
| Free Cash Flow Margin | - | -22180.88% | -151.34% | -1158.55% | -850.55% | |
| EBITDA | -87.21 | -64.85 | -28.41 | -58.67 | -53.02 | |
| EBITDA Margin | - | - | -84.81% | - | - | |
| D&A For EBITDA | 2.6 | 2.43 | 2.27 | 1.16 | 0.25 | |
| EBIT | -89.81 | -67.28 | -30.67 | -59.83 | -53.27 | |
| EBIT Margin | - | - | -91.58% | - | - | |
| Revenue as Reported | - | - | 33.49 | 4.93 | - | |
Source: S&P Capital IQ. Standard template.
Financial Sources.